Saltar al contenido
PivotalWire
Domingo 22 nov 2026SEC · NASDAQ biomédico

Calendario›SNY›lenalidomide

lenalidomide

Ensayo de Sanofi en Plasma Cell Myeloma (del registro, en inglés).

Fase
Fase 1
Estado
Completado
Participantes
90
previstos
Centros
12
Fin del objetivo primario
ene 2022
fecha real

Título oficial en el registro (en inglés): Study of Isatuximab Combined With Bortezomib + Cyclophosphamide + Dexamethasone (VCD) and Bortezomib + Lenalidomide + Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma (MM) Non Eligible for Transplant or No Intent for Immediate Transplantation

Qué significa cada fase y cada estado.

Estudio de intervención, de un solo grupo, abierto. Comenzó en sep 2015.

De principio a fin

  1. Empieza el ensayo (sep 2015)
  2. Lectura de resultados ene 2022 (real)
  3. Hoy

Los cambios los anota PivotalWire desde agosto de 2026; lo anterior no lo tenemos. El historial completo, versión a versión, está en ClinicalTrials.gov.

Qué mide

Assessment of dose-limiting toxicities (DLTs) in VCDI cohort (Up to 6 weeks per treated patient) (del registro, en inglés)

Cómo lo describe el promotor

En el documentoEn inglés, del registroPrimary Objectives: * VCDI cohort: * To determine the maximum tolerated dose (MTD) and recommended dose (RD) of SAR650984 isatuximab when administered in combination with bortezomib (Velcade®) , cyclophosphamide, and dexamethasone (VCDI) based on the dose-limiting toxicity(ies) (DLTs) observed in patients with newly diagnosed multiple myeloma non-eligible for transplantation * To evaluate safety and preliminary efficacy (overall response rate and complete response rate) of isatuximab administered at the selected dose in combination with bortezomib based regimin VCDI according to IMWG criteria. * VRDI Part A cohort and Part B cohort: * To evaluate the preliminary efficacy (complete response [CR] rate) of isatuximab administered at the selected dose in combination with bortezomib based regimen: VRDI, (bortezomib, lenalidomide, dexamethasone) according to IMWG criteria in adult patients with newly diagnosed MM non eligible for transplantation or no intent for immediate transplantation. Secondary Objectives: * VCDI cohort: * To characterize the overall safety profile of SAR650984 in combination with VCD regimen, including cumulative toxicities. * To characterize the pharmacokinetic (PK) profile of SAR650984/isatuximab and each combination drug in VCDI regimen. * To evaluate the immunogenicity of SAR650984 in combination treatments. * To evaluate the preliminary efficacy of VCDI regimen in terms of duration of response and progression-free survival. * To assess the relationship between clinical effects (adverse event [AE] and/or tumor response) and CD38 receptor density. * VRDI Part A cohort and Part B cohort: * To characterize the overall safety profile of isatuximab in combination with VRD regimen. * To evaluate the infusion duration (only applicable for VRDI Part B cohort) * To characterize the PK profile of isatuximab and each combination drug in VRDI regimen. * To evaluate the immunogenicity of isatuximab in combination treatments. * To evaluate the preliminary efficacy of VRDI regimen in terms of ORR, DOR, and PFS. * To evaluate the impact of M protein measurement without isatuximab interference (via the SEBIA HYDRASHIFT 2/4 isatuximab IFE test) on CR and BOR assessment. * To assess the relationship between clinical effects (AE and/or tumor response) and CD38 receptor density (only applicable for VRDI Part A cohort). * To assess MRD negativity rate in patients achieving a CR or VGPR and explore correlation with clinical outcome.

Más ensayos de SNY

EnsayoFaseEstadoLectura de resultados
Avalglucosidase alfa · Mini-COMETFase 2En marcha, sin reclutarsep 2019 (real)
Yellow fever vaccineFase 2En marcha, sin reclutarmay 2022 (real)
Yellow fever vaccine · VYF02Fase 2En marcha, sin reclutarjun 2022 (real)
SAR441344 IVFase 2En marcha, sin reclutarsep 2022 (real)
Meningococcal PolysaccharideFase 3En marcha, sin reclutarmar 2023 (real)
rilzabrutinib · LUMINA 2Fase 2En marcha, sin reclutarmay 2024 (real)

Todos los de SNY, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT02513186), actualizada en ene 2024.